Dr. Lewandrowski's early studies in the implementation of rapid bedside glucose testing in critical care and point of care and his approach to structuring quality assurance programs resulted in national adoption of his methods.
Kent Lewandrowski, MD is the Associate Chief for Laboratory and Molecular Medicine at the Massachusetts General Hospital Pathology Service. He is a Professor of Pathology at Harvard Medical School, with research interests in pancreatic pathology and the evaluation of point-of-care technologies. Dr. Lewandrowski is a member of the leadership team of Partners Healthcare Personalized Medicine. Read more about Dr. Lewandrowski's contributions to operations improvement, regulatory compliance, strategic planning, and quality improvement. He has published several studies on the impact of rapid point-of-care testing on outcomes in the emergency department, particularly in relation to reducing emergency room length-of-stay and reducing unnecessary hospital admissions. He is editor in chief of the medical journal "Point of Care: The Journal of Near Patient Testing Technology". Dr. Lewandrowski was trained in anatomic and clinical pathology at the Massachusetts General Hospital and has been on the staff of the department of Pathology since 1991.
Dr. Lewandrowski's research interests include point-of-care diagnostics, and serum cardiac markers. He also studies the pathology of the pancreas, including chemical and histopathologic features of pancreatic neoplasms and the pathology of acute experimental pancreatitis. For more information about research concepts, co-authors, and to see a timeline, visit Dr. Lewandrowski's profile at the Harvard Clinical and Translational Science Center.